玻璃体内注射卡铂联合贝伐单抗治疗难治性视网膜母细胞瘤的疗效

[Efficacy of intravitreal carboplatin plus bevacizumab in refractory retinoblastoma].

作者信息

Hou Xianru, Cheng Yong, Zhang Qi, Liang Jianhong, Li Xiaoxin

机构信息

Department of Ophthalmology People Eye Institute, People's Hospital, Peking University, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.

出版信息

Zhonghua Yan Ke Za Zhi. 2015 Feb;51(2):126-9.

PMID:25908004

Abstract

OBJECTIVES

To evaluate the efficacy of intravitreal carboplatin plus bevacizumab in refractory retinoblastoma.

METHODS

Perspective study.Eleven patients (11 eyes) with the diagnosis of refractory retinoblastoma were enrolled in Department of Ophthalmology of Peking University People's Hospital from June 2013 to March 2014. They underwent intravitreal carboplatin plus bevacizumab every 4 weeks, an average of 4.5 times of treatment.Observe for 3 months after the last treatment. Aqueous humor was taken for cytological and VEGF detection and retinal funds were taken photos for observation.Statistical analyses between experimental group and control group and before and after intravitreal injection within experimental group were performed with independent samples t test.

RESULTS

Tumor in vitreous cavity reduced significantly in seven patients, however, poor control in four cases, and three of them were recurrent after first-line treatment. Cytology detection for aqueous humor showed no tumor cells in all of them. Aqueous VEGF of patients with retinoblastoma (60.65 ± 6.20) was significantly higher than the control group (21.98 ± 6.91). The difference was statistically significant (t = 13.80, P < 0.01). And the aqueous VEGF content decreased significantly after treatment (t = 2.12, P < 0.05).

CONCLUSION

Intravitreal carboplatin plus bevacizumab, is a relatively safe, effective treatment for refractory retinoblastoma, however, ineffective for recurrent tumor.

摘要

目的

评估玻璃体内注射卡铂联合贝伐单抗治疗难治性视网膜母细胞瘤的疗效。

方法

前瞻性研究。2013年6月至2014年3月，北京大学人民医院眼科收治11例（11只眼）难治性视网膜母细胞瘤患者。每4周行1次玻璃体内注射卡铂联合贝伐单抗，平均治疗4.5次。末次治疗后观察3个月。采集房水进行细胞学及VEGF检测，并拍摄眼底照片进行观察。实验组与对照组之间以及实验组玻璃体内注射前后的统计分析采用独立样本t检验。

结果

7例患者玻璃体腔肿瘤明显缩小，4例控制不佳，其中3例一线治疗后复发。房水细胞学检测均未发现肿瘤细胞。视网膜母细胞瘤患者房水VEGF为（60.65±6.20），明显高于对照组（21.98±6.91）。差异有统计学意义（t = 13.80，P < 0.01）。治疗后房水VEGF含量明显降低（t = 2.12，P < 0.05）。